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Abstract
Background: There is robust evidence that schizophrenia is characterized by immune-inflammatory abnormalities, including 
variations on cytokine levels. The results of previous studies, however, are heterogeneous due to several confounding factors, 
such as the effects of antipsychotic drugs. Therefore, research on drug-naïve first-episode psychosis (FEP) patients is essential 
to elucidate the role of immune processes in that disorder.
Methods: The aim of this study is to compare cytokine levels (IL-2, IL-10, IL-4, IL-6, IFN-γ, TNF-α, and IL-17) in 
drug-naïve FEP patients both before and after treatment with risperidone for 10 weeks, and to investigate possible 
associations between cytokine levels and clinical responses to treatment and presence of depressive symptoms. It 
this study, we included 55 drug-naïve FEP patients who had repeated measurements of cytokine levels and 57 healthy 
controls.
Results: We found that FEP patients had significantly higher IL-6, IL-10 and TNF-α levels than healthy controls. After risperidone 
treatment, these three cytokines and additionally IL-4 decreased significantly. No significant difference was found between 
the post-treatment cytokine levels in FEP patients and in healthy controls, suggesting that these alterations in cytokine 
profiles are a state marker of FEP. No significant association was found between risperidone-induced changes in cytokines 
and the clinical response to treatment or the presence of depression. There was a significant inverse association between the 
risperidone-induced changes in IL-10 and the negative symptoms.
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Conclusions: In conclusion, our results show a specific cytokine profile in FEP patients (monocytic and regulatory T-cell 
activation) and suggest immunoregulatory effects of risperidone treatment, characterized by suppressant effects on 
monocytic, Th2, and T-regulatory functions.
Keywords: antipsychotic, cytokines, drug-naïve, FEP, immunology, inflammation, risperidone, schizophrenia
Introduction
Abnormalities in immune-inflammatory pathways have consist-
ently been described in schizophrenia (Smith and Maes, 1995; 
Anderson et  al., 2013). Increased levels of pro-inflammatory 
cytokines and T helper (Th) 1-like cytokines were reported in 
schizophrenia, suggesting, respectively, macrophage and T-cell 
activation (Miller et al., 2011). A recent meta-analysis showed an 
elevation in pro-inflammatory cytokine (and receptor) levels in 
the serum of drug-naïve first-episode psychosis (FEP) patients 
with higher levels of interleukin (IL)-1β, soluble IL-2 receptor 
(sIL-2R), IL-6, and tumor necrosis factor (TNF)-α, a profile indica-
tive of M1 (macrophage1) and Th1 activation (Upthegrove et al., 
2014). These changes in cytokine profile accompany the onset of 
the disorder (Borovcanin et al., 2012; Di Nicola et al., 2013).
Antipsychotics have a variety of effects on cytokine levels 
(Maes et al., 1994, 2000; Zajkowska and Mondelli, 2014). Tourjman 
et al. (2013), in a meta-analysis, found increased levels of sIL-2R 
and reduced levels of IL-1β and interferon (IFN)-γ after antipsy-
chotic treatment in individuals with schizophrenia. However, it has 
remained elusive whether these changes in cytokine levels are due 
to effects of the antipsychotic drugs per se, or whether they are 
a consequence of psychopathology improvement. Even using the 
same antipsychotic agent (e.g., risperidone), results remain het-
erogeneous, with differences between in vitro and in vivo studies, 
stages of illness, and schizophrenia subtypes. In vitro, Himmerich 
et  al. (2011) showed that several antipsychotics increase IL-17 
levels and that risperidone may inhibit Th1 cytokines (e.g., IL-12) 
and increase Th2 cytokines (e.g., IL-10) and pro-inflammatory 
cytokines, such as IL-6, IL-8, and TNF-α (Chen et al., 2012). On the 
other hand, Kato et al. (2007) found that risperidone significantly 
inhibits the production of IL-1β, IL-6, and TNF-α by IFN-γ-activated 
microglia. In an animal model of neuroinflammation using a 
lipopolysaccharide (LPS) challenge, atypical antipsychotics, includ-
ing risperidone, suppress TNF-α and IL-6, and up-regulate IL-10 
(Sugino et al., 2009). Interestingly, risperidone also prevented the 
increase of inflammatory parameters induced by LPS and restored 
anti-inflammatory pathways decreased by LPS (MacDowell et al., 
2013). In vivo, typical antipsychotics suppressed plasma IL-6 and 
soluble IL-6 receptors (Maes et al., 1995), whereas the administra-
tion of clozapine and risperidone increased sIL-2 receptor, IL-6, 
and TNF-α (Maes et al., 1994, 1997). More recently, it was shown 
that treatment with atypical antipsychotics may increase type-2 
cytokine serum levels in schizophrenia, and decreases IL-4, IL-6, 
and IL-27 levels (Borovcanin et al., 2013). Many confounding factors 
may result in inconsistent results among studies, including gender, 
smoking habits, age, stages of illness, general medical comorbidi-
ties, and differences between antipsychotic agents (Haack et al., 
1999). Furthermore, it has been demonstrated that subgroups of 
schizophrenia (e.g., depressed or treatment-resistant) may present 
distinct cytokine profiles (Noto et al., 2011, 2013).
The aim of this study was to delineate the effects of risperi-
done on the levels of M1 (IL-6, TNF-α), Th1 (IL-2, IFN-γ), Th2 (IL-4), 
and T-regulatory cell (IL-10) cytokines in a sample of drug-naïve 
FEP patients and to delineate whether the effects of risperidone 
on cytokine levels are related to a good clinical response or to 
changes in depressive symptoms in FEP patients.
Subjects and Methods
This study was conducted in accordance with the Declaration 
of Helsinki. The research protocol was approved by the Research 
Ethics Committee of the Universidade Federal de São Paulo, 
and all participants provided written informed consent prior to 
enrollment.
Subjects
We recruited antipsychotic-naïve FEP patients (n = 55) admitted to 
a psychiatric emergency unit in São Paulo, Brazil. For the purpose 
of the study, FEP was defined by a distinct period characterized by 
the emergence of psychotic symptoms. To delineate the beginning 
of the episode, we investigated the last period before the first onset 
of psychotic symptoms, including familiar interviews when neces-
sary. All patients fulfilled one of the following diagnoses, according 
to the criteria of the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition, using their Structured Clinical Interview 
(SCID-I): schizophrenia, schizophreniform disorder, brief psy-
chotic disorder, and psychotic disorders not otherwise specified. 
The mean time between the onset of psychotic symptoms and the 
introduction of treatment was 223 days (±435). A history of canna-
bis use was reported by 27.3% of the patients. Nevertheless, none of 
them fulfilled criteria for a substance-induced psychotic disorder. 
The sample included individuals between 16 and 40 years old, who 
had never used any antipsychotic before admission. Exclusion psy-
chiatric criteria were: psychotic episodes due to a general medical 
condition, substance-induced psychotic disorder, intellectual dis-
ability, and a psychotic episode associated with bipolar or major 
depressive disorders. General exclusion criteria were: acute and 
chronic general medical conditions associated with abnormalities 
in immune-inflammatory responses, such as infections, HIV, aller-
gies, pregnancy or the postpartum period; rheumatologic or immu-
nological conditions were also exclusionary criteria. In addition, 
individuals who had used medications with immunomodulatory 
effects such as non-steroidal anti-inflammatory drugs, corticoster-
oids, and immunosuppressant drugs were excluded.
All patients received risperidone as standard treatment. The 
mean dose of risperidone was 4.0 mg (±1.8). The titration was 
performed according to clinical judgment. Other medications 
were used in the period between both assessments, according 
to the symptomatology. The drugs used were benzodiazepine 
(16.4%), anticholinergic (9%), and an antidepressant (3.6%).
The comparison group consisted of antipsychotic-naïve, 
healthy volunteers (n = 57) assessed for personal and familiar 
history of psychiatric disorders according to the criteria of the 
SCID-I. Only individuals without a current or lifetime history of 
psychiatric disorders and with an absence of a major mental dis-
order in first-degree relatives were included. The general exclu-
sion criteria were the same as with the individuals with FEP.
The relative severity of illness dimensions was assessed 
using: (a) the Positive and Negative Syndrome Scale (PANSS; Kay 
et al., 1987); (b) the Clinical Global Impression Scale (CGI; Guy 
et al., 1976); (c) the Global Assessment of Functioning Scale (GAF; 
American Psychiatric Association, 2000); and (d) the Calgary 
Depression Scale for Schizophrenia (CDS; Addington et al., 1990). 
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Response to treatment was defined as a reduction of more than 
50% of baseline PANSS total score (Leucht et al., 2009). The per-
centage reduction in the total PANSS score from baseline to end-
point was calculated after subtracting the 30 minimum points of 
the total PANSS score (Leucht et al., 2009). We divided the patient 
group into those with and without depression using a threshold 
value of CDS > 5. According to the Brazilian version of CDS, this 
cutoff value presents a specificity of 92% and a sensitivity of 77% 
to identify major depression (Bressan et al., 1998).
Methods
Blood samples of 10 mL were withdrawn from all patients at admis-
sion, before the first dose of risperidone, and after a mean of 10.95 
weeks of treatment (standard deviation 5.7 weeks), and from all 
healthy controls after the SCID-I interview. Blood was immediately 
centrifuged and the serum was stored at −80◦C until thawed for assays 
of cytokines. All samples were thawed the same day and assays were 
carried out in a single run using the same batch of reagents. Multiple 
cytokines (IL-2, IL-10, IL-4, IL-6, IFN-γ, TNF-α, and IL-17) were measured 
by flow cytometry using the Cytometric Bead Array Human Th1/Th2/
Th17 Kit (BD Biosciences). Acquisition was performed with a FACS 
Canto II flow cytometer (BD Biosciences). The instrument was checked 
for sensitivity and overall performance with Cytometer Setup and 
Tracking beads (BD Biosciences) prior to data acquisition. Quantitative 
results were generated using FCAP Array v1.0.1 software (Soft Flow 
Inc.). IL-2 and IFN-γ were measurable only in a few patients and con-
trols and therefore analyses could not be carried out.
Statistical Analyses
Statistical analyses levels were performed using SPSS v.20. We 
used analyses of variance (ANOVAs) and analyses of contingency 
tables (χ2 tests) to examine differences in socio-demographic 
and clinical data between the study samples. Univariate and 
multivariate general linear model (GLM) analyses were used to 
examine the effects of explanatory variables (diagnostic groups 
and socio-demographic data) on the cytokine levels. Repeated 
measurements (RM) design ANOVAs were used to examine the 
effects of treatment (time) and time x diagnostic group inter-
actions as within-subject contrasts. Relationships between 
variables were assessed by means of regression analyses and 
Pearson’s product moment correlation analyses. We also used 
Spearman correlation calculations to check the results of para-
metric methods. Statistical significance was set at alpha ≤ 0.05 
(two-tailed).
Results
Characteristics of the Sample
Table 1 describes the socio-demographic and clinical data of FEP 
patients and healthy controls. No significant differences were 
found between the two groups in either age or gender. Without 
Bonferroni p correction for multiple statistical analyses and com-
parisons, there were significant differences in years of education 
and income between psychotic patients and controls. Table 1 also 
shows the mean values of the rating scales in the FEP patients.
Effect of Risperidone Treatment on Cytokines and 
Clinical Levels
Table  2 shows the cytokine level measurements at baseline 
and post-treatment in FEP patients when compared to healthy 
controls. Table  2 also shows the comparison between pre- and 
post-treatment cytokines and psychopathology data as a time 
factor and a time x gender interaction, analyzed with RM design 
ANOVAs. Treatment with risperidone significantly lowered IL-6, 
IL-4, IL-10, and TNF-α, while there was a trend towards increased 
IL-17 levels after treatment. There were no significant interactions 
between time x gender. Treatment with risperidone reduced the 
PANSS general, PANSS positive, CDS, CGI, and GAF scores. There 
was no significant effect of treatment with risperidone on the 
PANSS negative subscale score. Changes in the levels of cytokines 
were not correlated with the dosage of risperidone (p < 0.05).
Table 1. Socio-demographic and Clinical Characteristics of First-episode Psychosis (FEP) Patients and Healthy Controls (HC).
FEP n = 55 HC n = 57 F or Χ2 df p
Gender 1.90 1 0.168
Male 65.5% 52.6%
Female 34.5% 47.4%
Age 24.75 (±7.43) 26.61 (±7.53) -1.32 1/110 0.189
Marital status 4.30 1/2 0.117
Single 87.5% 78.8%
Marriage 7.5% 21.2%
Divorced 7.5% 0%
Years of education 15.15 1/1 <0.001
<11 years 47.5% 6.1%
≥11 years 52.5% 93.9%
Income (US dollars/per month) 363.85 (±262.67) 1148.65 (±857.43) 5.40 1/67 <0.001
Smoking 7.14 1/1 0.008
Yes 18.9% 0%
No 81.1% 100%
PANSS positive 28.27 (±5.53) -
PANSS negative 21.88 (±6.89)
PANSS general 49.12 (±13.12)
PANSS Total 99.27 (±20.64)
CDS 5.37 (±6.00) -
CGI 5.13 (±0.74) -
GAF 27.26 (±10.08) -
CDS: Calgary Depression Scale; CGI: Clinical Global Impression; GAF: Global Assessment of Functioning; PANSS: Positive and Negative Syndrome Scale,  
Results are shown as mean ± standard deviation.
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Results of ANOVAs showed that pre-treatment IL-6 levels in 
FEP patients were significantly higher than in controls (F = 9.89, 
df = 1/112, p = 0.002), whereas post-treatment IL-6 values in FEP 
patients were not significantly different from those in controls 
(F = 0.41, df = 1/110, p = 0.524). Pre-treatment IL-4 levels of FEP 
patients were not significantly different from IL-4 levels in con-
trols (F  =  2.15, df  =  1/110, p  =  0.145), whereas the post-treat-
ment IL-4 levels were significantly lower in FEP patients than 
in controls (F = 6.00, df = 1/110, p = 0.016). The pre-treatment 
IL-10 levels of FEP patients were significantly higher than those 
in healthy controls (F  =  18.82, df  =  1/110, p  <  0.001), whereas 
the post-treatment IL-10 values in FEP patients were not sig-
nificantly different from those in controls (F = 0.01, df = 1/110, 
p  =  0.939). The baseline TNF-α values in FEP patients were 
significantly higher than those in healthy controls (F  =  8.87, 
df = 1/110, p = 0.004), whereas the post-treatment TNF-α values 
in FEP patients were not significantly different from those in 
controls (F = 3.90, df = 1/110, p = 0.051). There were no significant 
differences between the IL-17 values in the controls and the 
baseline (F = 1.27, df = 1/110, p = 0.260) or post-treatment IL-17 
(F = 0.91, df = 1/110, p = 0.343) values in FEP patients. Multivariate 
GLM analysis showed that the pre-treatment levels of the five 
cytokines (IL-4, IL-6, IL-10, TNF-α, and IL-17) in the FEP patients 
were significantly different from controls (F = 5.74, df = 5/106, 
p  <  0.001), while there were no significant differences in the 
post-treatment levels of the five cytokines in the FEP patients 
and the controls (F = 2.13, df = 5/106, p = 0.067). We examined 
the effects of current tobacco use disorders on the cytokine lev-
els and a possible interaction with the effects of risperidone. 
Multivariate GLM analysis did not show any significant effect 
of current tobacco use disorder on the cytokine levels (F = 0.92, 
df = 5/64, p = 0.472). We were unable to find any significant time 
x current tobacco use disorder and diagnostic group x time x 
current tobacco use disorder for any of the five cytokine levels.
Responder and Non-Responders Analysis on Clinical 
Parameters
Table  3 shows the results of RM design ANOVAs with time 
(pre- and post-treatment PANSS and CDS scores) and time x 
responder status (responder versus non-responder status based 
on changes in the PANSS total score) as within-subject contrasts. 
RM design ANOVAs showed significant interactions between time 
x responder status for the total PANSS as well as the PANSS posi-
tive, negative, and general psychopathology subscales. Treatment 
with risperidone showed a significant suppressant effect on 
the CDS score, although there were no significant differences 
between responders and non-responders to treatment.
Table 3. Effects of Treatment with Risperidone on Psychopathology in First-episode Psychosis (FEP) Patients, Comparing the Pre- and Post- 
treatment Data in FEP Patients Who Were Responders or Non-responders to Treatment with Risperidone.
Responders Non-responders Time F-value* df p
Time x  
Responder  
status F-value* df P
CDS PRE 6.56 (±5.89) 4.79 (±6.54) 5.91 1/35 0.020 1.66 1/35 0.207
POST 2.13 (±3.30) 3.42 (±5.11)
PANSS Total PRE 104.39 (±21.60) 97.10 (±20.64) 163.76 1/35 <0.001 39.41 1/35 <0.001
POST 54.33 (±8.34) 80.00 (±14.82)
PANSS Pos PRE 29.89 (±4.78) 26.95 (±6.09) 255.65 1/35 <0.001 21.36 1/35 <0.001
POST 10.61 (±2.52) 16.32 (±5.54)
PANSS Neg PRE 22.44 (±8.06) 22.00 (±6.10) 2.99 1/35 0.09 19.08 1/35 <0.001
POST 16.00 (±4.70) 24.79 (±7.17)
PANSS Gen PRE 52.06 (±13.58) 48.16 (±13.16) 75.87 1/35 <0.001 15.58 1/35 <0.001
POST 27.72 (±4.08) 39.00 (±7.42)
CDS: Calgary Depression Scale; PANSS: Positive and Negative Syndrome Scale.  
*Results of repeated measurements design ANOVAs with risperidone treatment as the time factor and gender as the inter-individual factor. Results are shown as 
mean ± standard deviation.
Table 2. Effects of Treatment with Risperidone on Serum Cytokine Levels in First-episode Psychosis (FEP) Patients. The Pre- and Post-treatment 
Data in the FEP Patients Are Compared with Those in Healthy Controls.
HC (n = 57)
FEP Pre
(n = 55)
FEP Post 
(n = 55) Time F-value* df p
Time x Gender 
F-value* p
IL-6 0.77 (±0.04) 1.64 (±1.77) 0.90 (±0.81) 9.81 1/53 0.003 0.11 0.745
IL-4 0.24 (±0.63) 0.43 (±0.78) 0.03 (±0.09) 16.21 1/53 <0.001 0.14 0.291
IL-10 0.20 (±0.45) 0.84 (±1.01) 0.21 (±0.34) 18.71 1/53 <0.001 0.57 0.453
TNF-α 0.16 (±0.51) 0.63 (±1.07) 0.02 (±0.02) 17.69 1/53 <0.001 0.00 0.985
IL-17 4.26 (±11.87) 2.31 (±4.76) 6.70 (±15.11) 3.11 1/53 0.083 0.49 0.489
PANSS Pos - 28.38 (±5.62) 13.54 (±5.17) 118.65 1/35 <0.001 0.84 0.773
PANSS Neg - 22.22 (±7.02) 20.51 (±7.48) 0.41 1/35 0.435 0.41 0.525
PANSS Gen - 50.05 (±13.33) 33.51 (±8.25) 47.70 1/35 <0.001 1.51 0.227
PANSS Total - 100.65 (±21.14) 60.4 (±17.66) 60.45 1/35 <0.001 0.35 0.557
CDS - 5.60 (±6.23) 2.83 (±4.37) 7.99 1/33 0.008 2.42 0.129
CGI - 5.18 (±0.73) 3.33 (±1.31) 40.24 1/31 <0.001 0.77 0.388
GAF - 27.00 (±9.56) 57.12 (±16.63) 76.83 1/31 <0.001 1.88 0.180
CDS: Calgary Depression Scale; CGI: Clinical Global Impression; GAF: Global Assessment of Functioning; IL: interleukin; PANSS: Positive and Negative Syndrome 
Scale; TNF: tumor necrosis factor.  
Results are shown as mean ± standard deviation and are in pg/mL.*Results of repeated measurements design ANOVAs are with risperidone treatment as time factor 
and gender as between-subject factor (and performed on FEP Pre versus FEP Post).
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Table 4 shows the results of RM design ANOVAs with time (pre- 
and post-treatment cytokine levels) and time x responder status 
(responders versus non-responder status to treatment) as within-
subject contrasts. There were no significant interactions between 
time x treatment responder status for any of the cytokines.
Correlation Between Cytokines Levels and the 
Presence of Depression
Table 5 shows the results of RM design ANOVAs with time (pre- 
and post-treatment cytokines data) and time x diagnostic depres-
sion groups (patients divided according to the baseline CDS 
values using a threshold value >5) as within-subject contrasts. We 
found significant interactions between time x diagnostic groups 
for IL-4 and TNF-α. Thus, treatment with risperidone significantly 
decreased IL-4 and TNF-α in FEP patients with depressive symp-
toms and not in those without depressive symptoms.
Correlation Between Cytokines Levels and 
Psychopathology
We also examined the correlations between the changes in 
cytokines and psychopathology levels from baseline to end-
point. The changes from baseline to endpoint were computed as 
the residual values obtained by the regression of the endpoint 
values on the baseline values (and secondly by computing the 
delta values: that is, endpoint minus the baseline values). There 
were significant correlations between the residual changes in the 
PANSS positive and PANSS negative subscale scores (r = 0.336, 
p  =  0.042). There were no significant correlations between the 
residual changes in the CDS score and those in the PANSS total 
or PANSS positive or negative subscales. There was a significant 
inverse association between the residual changes in IL-10 and 
those in the PANSS negative score (r = -0.480, p = 0.001). There 
were no significant associations between the residual changes 
in the CDS scores and any of the cytokines measured.
In order to examine possible effects of age on the effects of ris-
peridone, we carried out RM ANOVAs with age groups as an addi-
tional factor. The study sample was divided into two age groups: 
subjects aged <20 years old (n = 23) and subjects ≥20 years old 
(n = 32). We did not detect significant interactions between time 
and age groups on IL-6 (F = 3.91, df = 1/53, p = 0.053), IL-4 (F = 1.23, 
df = 1/53, p  = 0.272), IL-10 (F = 0.24, df = 1/53, p  = 0.628), TNFα 
(F = 1.45, df = 1/53, p = 0.234), or IL-17 (F = 0.82, df = 1/53, p = 0.370).
Discussion
The first major finding of this study is that treatment with 
risperidone for 10 weeks had a significant suppressant effect 
Table 4. Effects of Treatment with Risperidone on Serum Cytokine Levels in First-episode Psychosis (FEP) Patients, Comparing the Pre- and 
Posttreatment Data in the FEP Patients Between Treatment Responders and Non-responders.
Responders Non Responders Time F-value* df p
Time x
Responder  
status F-value* df p
IL-6 PRE 1.92 (±2.01) 1.49 (±1.95) 6.21 1/35 0.018 0.00 1/35 0.950
POST 1.09 (±1.09) 0.70 (±0.44)
IL-4 PRE 0.48 (±0.18) 0.34 (±0.78) 8.73 1/35 0.006 0.17 1/35 0.681
POST 0.05 (±0.14) 0.02 (±0.05)
IL-10 PRE 1.13 (±1.13) 0.75 (±0.89) 13.54 1/35 <0.001 0.14 1/35 0.715
POST 0.38 (±0.47) 0.13 (±0.26)
TNF-α PRE 0.80 (±1.46) 0.42 (±0.71) 11.23 1/35 0.002 0.98 1/35 0.330
POST 0.05 (±0.17) 0.10 (±0.00)
IL-17 PRE 2.41 (±4.22) 3.81 (±6.52) 2.57 1/35 0.118 0.80 1/35 0.378
POST 9.99 (±21.93) 5.97 (±13.17)
IL: interleukin; TNF: tumor necrosis factor.  
*Results of repeated measurements design ANOVAs with risperidone treatment as the time factor and responder status as the inter-individual factor. Cytokine levels 
are shown as mean ± standard deviation and are in pg/mL.
Table 5. Effects of Treatment with Risperidone on Serum Cytokine Levels in First-episode Psychosis (FEP) Patients, Comparing the Pre- and 
Posttreatment Data in the FEP Patients with (CDS > 5) and Without (CDS ≤ 5) Depression as Measured by Means of the Calgary Depression Scale 
Score.
CDS ≤ 5 CDS > 5 F-value* df p F-value* df p
IL-6 PRE 1.46(±1.87) 1.75 (±1.78) 5.13 1/34 0.030 0.19 1/34 0.668
POST 0.89 (±1.09) 0.91 (±1.22)
IL-4 PRE 0.17 (±0.48) 0.85 (±1.01) 14.77 1/34 <0.001 6.19 1/34 0.013
POST 0.20 (±0.05) 0.06 (±0.16)
IL-10 PRE 0.98 (±1.13) 0.92 (±0.84) 14.48 1/34 <0.001 0.07 1/34 0.800
POST 0.29 (±0.44) 0.14 (±0.23)
TNF-α PRE 0.27 (±0.58) 1.24 (±1.61) 18.00 1/34 <0.001 7.37 1/34 0.010
POST 0.01 (±0.00) 0.07 (±0.21)
IL-17 PRE 1.93 (±0.35) 5.49 (±7.60) 1.46 1/34 0.235 0.48 1/34 0.495
POST 8.12 (±19.76) 7.18 (±15.33)
CDS: Calgary Depression Scale; IL: interleukin; TNF: tumor necrosis factor.  
Cytokine levels are shown as mean ± standard deviation and are in pg/mL. *Results of repeated measurements design ANOVAs with risperidone treatment as the 
time factor and depression as the inter-individual factor.
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on several serum cytokine levels. The baseline levels of IL-6, 
IL-10, and TNF-α were significantly higher in drug-naïve FEP 
patients when compared to healthy controls but were normal-
ized after 10 weeks of risperidone treatment, whereas IL-4 lev-
els reduced. These results suggest a specific cytokine profile 
in FEP patients characterized by monocytic and T-regulatory 
cell responses, and indicate that treatment with risperidone 
may normalize these responses and additionally decrease 
Th2 functions. Based on our results, we conclude that risp-
eridone seems to normalize an aberrant cytokine profile in 
FEP. Therefore, the immune effects of risperidone in FEP can-
not be described as either anti-inflammatory or “negative 
immunoregulatory”.
Our results are partially in agreement with previous papers 
reporting on the effects of risperidone and other antipsy-
chotic agents. In a drug-naïve FEP sample, Song et  al. (2014) 
found increased levels of baseline IL-1β, IL-6, and TNF-α in FEP 
patients compared to controls. Following risperidone treatment, 
they found an increase in TNF-α and an initial decrease of IL-6 
levels succeeded by an increase to baseline levels. Risperidone 
attenuates the increase of inflammatory parameters induced 
by LPS and restores anti-inflammatory pathways decreased 
by LPS (MacDowell et  al., 2013). Other studies found different 
cytokine responses to risperidone, likely attributable to differ-
ences in media (immune cells versus microglia), in vitro and in 
vivo studies, and staging of illness and schizophrenia subtypes 
(Kato et  al., 2007; Sugino et  al., 2009; Himmerich et  al., 2011; 
Chen et al., 2012; Borovcanin et al., 2013; MacDowell et al., 2013; 
Song et al., 2014).
Significant immune effects of other antipsychotic drugs in 
FEP patients have been reported (see Tourjman et  al., 2013). 
These previous studies found a significant decrease of IL-6, 
IL-4, and IL-27 after antipsychotic treatment in FEP (Kubistova 
et al., 2012; Borovcanin et al., 2013), but not of TNF-α (Kubistova 
et al., 2012). In a recent meta-analysis (Tourjman et al., 2013), 23 
studies were included showing that antipsychotics may have 
anti-inflammatory effects. However, none of the cytokine levels 
reduced after risperidone treatment in our study were signifi-
cant in this meta-analysis. These differences may be explained 
by differences in study samples and antipsychotic agents, such 
as FEP patients treated with risperidone in our study versus 
chronic patients treated with different antipsychotics in the 
meta-analysis. In another meta-analysis, Miller et  al. (2011) 
concluded that some cytokines (IL-1β, IL-6, and TGF-β) may be 
state markers for the acute phase of schizophrenia, while other 
immune markers (IL-12, IFN-β, TNF-β, and sIL-2R) may be trait 
markers. However, in our sample, we did not find any cytokine 
that could function as a trait marker because all cytokines that 
were initially increased in FEP were normalized after risperi-
done treatment.
The second major finding of this study is that risperidone 
treatment improved psychopathology, and that this effect 
was not related to risperidone-induced changes in cytokine 
levels from baseline to endpoint. Interestingly, risperidone 
treatment had a significant effect on the severity of positive 
and depressive symptoms and general pathology as meas-
ured with the CGI or GAF, but had no significant effect on the 
negative symptoms. We were unable to establish a significant 
association between a good clinical response to treatment (as 
defined by a 50% reduction in the PANSS total scale) and the 
risperidone-induced changes in cytokine levels. Therefore, 
we conclude that the normalization of the cytokine profile 
by risperidone treatment should be ascribed to the actions of 
risperidone, and that it occurs independently from changes 
in psychopathological improvement. Interestingly, we could 
not find a correlation between the doses of risperidone and 
the post-treatment cytokine levels or risperidone-induced 
cytokine changes.
Another important question is whether there are signifi-
cant differences in the effects of risperidone between individ-
uals with and without depression (as measured with the CDS 
score). We found that treatment with risperidone significantly 
decreased IL-4 and TNF-α in FEP patients with depressive symp-
toms, but not in those without depressive symptoms. These 
findings show that risperidone may have different immune 
effects in FEP patients with depression as compared to FEP 
patients without depression.
In regard to the effect of risperidone on psychopathology, 
we found that while there was no significant overall effect of 
risperidone treatment on the PANSS negative symptom score, 
there was a significant time x responder treatment interaction. 
Thus, after treatment with risperidone the negative symp-
tom severity was increased compared to baseline, whereas in 
responders negative symptoms were decreased. This suggests 
that non-reactivity in negative symptoms is strongly associ-
ated with non-responder status. Interestingly, the risperidone-
induced changes in the negative symptoms were strongly 
and inversely correlated with those in IL-10. Thus, it appears 
that a comparatively smaller suppressant effect of risperi-
done on IL-10 may be protective against negative symptoms. 
This is important, since IL-10 is an anti-inflammatory and 
immunoregulatory cytokine that has neuroprotective effects 
(Arimoto et al., 2007). Such an effect may be related to a better 
clinical outcome.
The longitudinal assessment of drug-naïve FEP patients 
with the standardization of the antipsychotic treatment is 
the main strength of our study and adds to the current litera-
ture on the immunomodulation of antipsychotics, specifically 
risperidone. Therefore, this study was controlled for two very 
important confounding factors. However, some limitations 
should be mentioned. IL-2 and IFN-γ serum levels were meas-
urable only in a few patients and controls and therefore analy-
ses could not be carried out. Furthermore, the analysis was 
made after 10 weeks, and it would have been more informa-
tive to have data also at later time points. A  longer follow-
up period could be helpful to clarify the long-term effects of 
risperidone.
In summary, we found that risperidone significantly normal-
ized the initially-abnormal cytokine profiles in FEP patients. 
This normalization of the cytokine profiles was, however, not 
associated with a good clinical response to risperidone. This 
suggests that the normalization of the cytokine profiles was 
due to specific effects of risperidone and was not secondary to 
symptomatic improvement. The inverse correlation between 
risperidone-induced changes in IL-10 and negative symptoms 
indicates that IL-10 may have protective effects against negative 
symptoms.
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